WordNet
- (medicine) any disturbance in the functioning of an organ or body part or a disturbance in the functioning of a social group; "erectile dysfunction"; "sexual relationship dysfunction" (同)disfunction
- of or relating to a systole or happening during a systole
PrepTutorEJDIC
- 機能障害,機能不全
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2012/07/15 03:08:10」(JST)
wiki en
| Heart failure | |
|---|---|
| Classification and external resources | |
The major signs and symptoms of heart failure. |
|
| ICD-10 | I50 |
| ICD-9 | 428.0 |
| DiseasesDB | 16209 |
| MedlinePlus | 000158 |
| eMedicine | med/3552 emerg/108 radio/189 med/1367150 ped/2636 |
| MeSH | D006333 |
Heart failure (HF), often called congestive heart failure (CHF) or congestive cardiac failure (CCF), is an inability of the heart to provide sufficient pump action to distribute blood flow to meet the needs of the body.[1][2][3] Heart failure can cause a number of symptoms including shortness of breath, leg swelling, and exercise intolerance. The condition is diagnosed with echocardiography and blood tests. Treatment commonly consists of lifestyle measures such as smoking cessation, light exercise including breathing protocols, decreased salt intake and other dietary changes) and medications. Sometimes it is treated with implanted devices (pacemakers or ventricular assist devices) and occasionally a heart transplant.
Common causes of heart failure include myocardial infarction and other forms of ischemic heart disease, hypertension, valvular heart disease, and cardiomyopathy.[4] The term "heart failure" is sometimes incorrectly used to describe other cardiac-related illnesses, such as myocardial infarction (heart attack) or cardiac arrest, which can cause heart failure but are not equivalent to heart failure.
Heart failure is a common, costly, disabling, and potentially deadly condition.[4] In developed countries, around 2% of adults suffer from heart failure, but in those over the age of 65, this increases to 6–10%.[4][5]
Contents
|
Terminology
Heart failure is a global term for the physiological state in which cardiac output is insufficient in meeting the needs of the body and lungs. Often termed "congestive heart failure" or CHF, this is most commonly caused when cardiac output is low and the body becomes congested with fluid.[6]
It may also occur when the body's requirements for oxygen and nutrients are increased and the demand outstrips what the heart can provide, (termed "high output cardiac failure").[7] This can occur from severe anemia, Gram negative septicaemia, beriberi (vitamin B1/thiamine deficiency), thyrotoxicosis, Paget's disease, arteriovenous fistulae, or arteriovenous malformations.
Fluid overload is a common problem for people with heart failure but is not synonymous with it. Patients with treated heart failure will often be euvolaemic (a term for normal fluid status), or more rarely, dehydrated.
Medical professionals use the words "acute" to mean of rapid onset and "chronic" of long duration. Chronic heart failure is therefore a long term situation, usually with stable treated symptomatology.
Acute decompensated heart failure is a term used to describe exacerbated or decompensated heart failure, referring to episodes in which a patient can be characterized as having a change in heart failure signs and symptoms resulting in a need for urgent therapy or hospitalization.[8]
There are several terms which are closely related to heart failure, and may be the cause of heart failure, but should not be confused with it:
- Cardiac arrest and asystole refer to situations in which there is no cardiac output at all. Without urgent treatment these result in sudden death.
- Myocardial infarction ("Heart attack") refers to heart muscle damage due to insufficient blood supply, usually as a result of a blocked coronary artery.
- Cardiomyopathy refers specifically to problems within the heart muscle, and these problems can result in heart failure. Ischemic cardiomyopathy implies that the cause of muscle damage is coronary artery disease. Dilated cardiomyopathy implies that the muscle damage has resulted in enlargement of the heart. Hypertrophic cardiomyopathy involves enlargement and thickening of the heart muscle.
Classification
There are many different ways to categorize heart failure, including:
- the side of the heart involved (left heart failure versus right heart failure). Left heart failure compromises aortic flow to the body and brain. Right heart failure compromises pulmonic flow to the lungs. Mixed presentations are common, especially when the cardiac septum is involved.
- whether the abnormality is due to insufficient contraction (systolic dysfunction), or due to insufficient relaxation of the heart (diastolic dysfunction), or to both.
- whether the problem is primarily increased venous back pressure (preload), or failure to supply adequate arterial perfusion (afterload).
- whether the abnormality is due to low cardiac output with high systemic vascular resistance or high cardiac output with low vascular resistance (low-output heart failure vs. high-output heart failure).
- the degree of functional impairment conferred by the abnormality (as reflected in the New York Heart Association Functional Classification[9])
- the degree of coexisting illness: i.e. heart failure/systemic hypertension, heart failure/pulmonary hypertension, heart failure/diabetes, heart failure/renal failure, etc.
Functional classification generally relies on the New York Heart Association functional classification. The classes (I-IV) are:
- Class I: no limitation is experienced in any activities; there are no symptoms from ordinary activities.
- Class II: slight, mild limitation of activity; the patient is comfortable at rest or with mild exertion.
- Class III: marked limitation of any activity; the patient is comfortable only at rest.
- Class IV: any physical activity brings on discomfort and symptoms occur at rest.
This score documents severity of symptoms, and can be used to assess response to treatment. While its use is widespread, the NYHA score is not very reproducible and doesn't reliably predict the walking distance or exercise tolerance on formal testing.[10]
In its 2001 guidelines the American College of Cardiology/American Heart Association working group introduced four stages of heart failure:[11]
- Stage A: Patients at high risk for developing HF in the future but no functional or structural heart disorder.
- Stage B: a structural heart disorder but no symptoms at any stage.
- Stage C: previous or current symptoms of heart failure in the context of an underlying structural heart problem, but managed with medical treatment.
- Stage D: advanced disease requiring hospital-based support, a heart transplant or palliative care.
The ACC staging system is useful in that Stage A encompasses "pre-heart failure" — a stage where intervention with treatment can presumably prevent progression to overt symptoms. ACC Stage A does not have a corresponding NYHA class. ACC Stage B would correspond to NYHA Class I. ACC Stage C corresponds to NYHA Class II and III, while ACC Stage D overlaps with NYHA Class IV.
Signs and symptoms
A man with congestive heart failure and marked jugular venous distension. External jugular vein marked by an arrow.
Signs
Left-sided failure
Common respiratory signs are tachypnea (increased rate of breathing) and increased work of breathing (non-specific signs of respiratory distress). Rales or crackles, heard initially in the lung bases, and when severe, throughout the lung fields suggest the development of pulmonary edema (fluid in the alveoli). Cyanosis which suggests severe hypoxemia, is a late sign of extremely severe pulmonary edema.
Additional signs indicating left ventricular failure include a laterally displaced apex beat (which occurs if the heart is enlarged) and a gallop rhythm (additional heart sounds) may be heard as a marker of increased blood flow, or increased intra-cardiac pressure. Heart murmurs may indicate the presence of valvular heart disease, either as a cause (e.g. aortic stenosis) or as a result (e.g., mitral regurgitation) of the heart failure.
Right-sided failure
Physical examination may reveal pitting peripheral edema, ascites, and hepatomegaly. Jugular venous pressure is frequently assessed as a marker of fluid status, which can be accentuated by eliciting hepatojugular reflux. If the right ventricular pressure is increased, a parasternal heave may be present, signifying the compensatory increase in contraction strength.
Biventricular failure
Dullness of the lung fields to finger percussion and reduced breath sounds at the bases of the lung may suggest the development of a pleural effusion (fluid collection in between the lung and the chest wall). Though it can occur in isolated left- or right-sided heart failure, it is more common in biventricular failure because pleural veins drain both into the systemic and pulmonary venous system. When unilateral, effusions are often right sided.
Symptoms
Heart failure symptoms are traditionally and somewhat arbitrarily divided into "left" and "right" sided, recognizing that the left and right ventricles of the heart supply different portions of the circulation. However, heart failure is not exclusively backward failure (in the part of the circulation which drains to the ventricle).
There are several other exceptions to a simple left-right division of heart failure symptoms. Left sided forward failure overlaps with right sided backward failure. Additionally, the most common cause of right-sided heart failure is left-sided heart failure. The result is that patients commonly present with both sets of signs and symptoms.
Left-sided failure
Backward failure of the left ventricle causes congestion of the pulmonary vasculature, and so the symptoms are predominantly respiratory in nature. Backward failure can be subdivided into failure of the left atrium, the left ventricle or both within the left circuit. The patient will have dyspnea (shortness of breath) on exertion (dyspnée d'effort) and in severe cases, dyspnea at rest. Increasing breathlessness on lying flat, called orthopnea, occurs. It is often measured in the number of pillows required to lie comfortably, and in severe cases, the patient may resort to sleeping while sitting up. Another symptom of heart failure is paroxysmal nocturnal dyspnea a sudden nighttime attack of severe breathlessness, usually several hours after going to sleep. Easy fatigueability and exercise intolerance are also common complaints related to respiratory compromise.
"Cardiac asthma" or wheezing may occur.
Compromise of left ventricular forward function may result in symptoms of poor systemic circulation such as dizziness, confusion and cool extremities at rest.
Right-sided failure
Backward failure of the right ventricle leads to congestion of systemic capillaries. This generates excess fluid accumulation in the body. This causes swelling under the skin (termed peripheral edema or anasarca) and usually affects the dependent parts of the body first (causing foot and ankle swelling in people who are standing up, and sacral edema in people who are predominantly lying down). Nocturia (frequent nighttime urination) may occur when fluid from the legs is returned to the bloodstream while lying down at night. In progressively severe cases, ascites (fluid accumulation in the abdominal cavity causing swelling) and hepatomegaly (enlargement of the liver) may develop. Significant liver congestion may result in impaired liver function, and jaundice and even coagulopathy (problems of decreased blood clotting) may occur.
Causes
Chronic heart failure
The predominance of causes of heart failure are difficult to analyze due to challenges in diagnosis, differences in populations, and changing prevalence of causes with age.
A 19 year study of 13000 healthy adults in the United States (the National Health and Nutrition Examination Survey (NHANES I) found the following causes ranked by Population Attributable Risk score:[12]
- Ischaemic heart disease 62%
- Cigarette smoking 16%
- Hypertension (high blood pressure)10%
- Obesity 8%
- Diabetes 3%
- Valvular heart disease 2% (much higher in older populations)
An Italian registry of over 6200 patients with heart failure showed the following underlying causes:[13]
- Ischaemic heart disease 40%
- Dilated cardiomyopathy 32%
- Valvular heart disease 12%
- Hypertension 11%
- Other 5%
Rarer causes of heart failure include:
- Viral myocarditis (an infection of the heart muscle)
- Infiltrations of the muscle such as amyloidosis
- HIV cardiomyopathy (caused by human immunodeficiency virus)
- Connective tissue diseases such as systemic lupus erythematosus
- Abuse of drugs such as alcohol and cocaine
- Pharmaceutical drugs such as chemotherapeutic agents
- Arrhythmias
Obstructive sleep apnea (a condition of sleep wherein disordered breathing overlaps with obesity, hypertension, and/or diabetes) is regarded as an independent cause of heart failure.
Acute decompensated heart failure
Main article: Acute decompensated heart failure
Chronic stable heart failure may easily decompensate. This most commonly results from an intercurrent illness (such as pneumonia), myocardial infarction (a heart attack), arrhythmias, uncontrolled hypertension, or a patient's failure to maintain a fluid restriction, diet, or medication.[14] Other well recognized precipitating factors include anemia and hyperthyroidism which place additional strain on the heart muscle. Excessive fluid or salt intake, and medication that causes fluid retention such as NSAIDs and thiazolidinediones, may also precipitate decompensation.[15]
Pathophysiology
| This section needs additional citations for verification. (September 2010) |
Heart failure is caused by any condition which reduces the efficiency of the myocardium, or heart muscle, through damage or overloading. As such, it can be caused by as diverse an array of conditions as myocardial infarction (in which the heart muscle is starved of oxygen and dies), hypertension (which increases the force of contraction needed to pump blood) and amyloidosis (in which protein is deposited in the heart muscle, causing it to stiffen). Over time these increases in workload will produce changes to the heart itself:
- Reduced force of contraction, due to overloading of the ventricle. In a healthy heart, increased filling of the ventricle results in increased force of contraction (by the Frank–Starling law of the heart) and thus a rise in cardiac output. In heart failure this mechanism fails, as the ventricle is loaded with blood to the point where heart muscle contraction becomes less efficient. This is due to reduced ability to cross-link actin and myosin filaments in over-stretched heart muscle.[16]
- A reduced stroke volume, as a result of a failure of systole, diastole or both. Increased end systolic volume is usually caused by reduced contractility. Decreased end diastolic volume results from impaired ventricular filling – as occurs when the compliance of the ventricle falls (i.e. when the walls stiffen).
- Reduced spare capacity. As the heart works harder to meet normal metabolic demands, the amount cardiac output can increase in times of increased oxygen demand (e.g. exercise) is reduced. This contributes to the exercise intolerance commonly seen in heart failure. This translates to the loss of one's cardiac reserve. The cardiac reserve refers to the ability of the heart to work harder during exercise or strenuous activity. Since the heart has to work harder to meet the normal metabolic demands, it is incapable of meeting the metabolic demands of the body during exercise.
- Increased heart rate, stimulated by increased sympathetic activity[17] in order to maintain cardiac output. Initially, this helps compensate for heart failure by maintaining blood pressure and perfusion, but places further strain on the myocardium, increasing coronary perfusion requirements, which can lead to worsening of ischemic heart disease. Sympathetic activity may also cause potentially fatal arrhythmias.
- Hypertrophy (an increase in physical size) of the myocardium, caused by the terminally differentiated heart muscle fibres increasing in size in an attempt to improve contractility. This may contribute to the increased stiffness and decreased ability to relax during diastole.
- Enlargement of the ventricles, contributing to the enlargement and spherical shape of the failing heart. The increase in ventricular volume also causes a reduction in stroke volume due to mechanical and contractile inefficiency.[18]
The general effect is one of reduced cardiac output and increased strain on the heart. This increases the risk of cardiac arrest (specifically due to ventricular dysrhythmias), and reduces blood supply to the rest of the body. In chronic disease the reduced cardiac output causes a number of changes in the rest of the body, some of which are physiological compensations, some of which are part of the disease process:
- Arterial blood pressure falls. This destimulates baroreceptors in the carotid sinus and aortic arch which link to the nucleus tractus solitarius. This center in the brain increases sympathetic activity, releasing catecholamines into the blood stream. Binding to alpha-1 receptors results in systemic arterial vasoconstriction. This helps restore blood pressure but also increases the total peripheral resistance, increasing the workload of the heart. Binding to beta-1 receptors in the myocardium increases the heart rate and make contractions more forceful, in an attempt to increase cardiac output. This also, however, increases the amount of work the heart has to perform.
- Increased sympathetic stimulation also causes the hypothalamus to secrete vasopressin (also known as antidiuretic hormone or ADH), which causes fluid retention at the kidneys. This increases the blood volume and blood pressure.
- Reduced perfusion (blood flow) to the kidneys stimulates the release of renin – an enzyme which catalyses the production of the potent vasopressor angiotensin. Angiotensin and its metabolites cause further vasocontriction, and stimulate increased secretion of the steroid aldosterone from the adrenal glands. This promotes salt and fluid retention at the kidneys, also increasing the blood volume.
- The chronically high levels of circulating neuroendocrine hormones such as catecholamines, renin, angiotensin, and aldosterone affects the myocardium directly, causing structural remodelling of the heart over the long term. Many of these remodelling effects seem to be mediated by transforming growth factor beta (TGF-beta), which is a common downstream target of the signal transduction cascade initiated by catecholamines[19] and angiotensin II,[20] and also by epidermal growth factor (EGF), which is a target of the signaling pathway activated by aldosterone[21]
- Reduced perfusion of skeletal muscle causes atrophy of the muscle fibres. This can result in weakness, increased fatigueability and decreased peak strength - all contributing to exercise intolerance.[22]
The increased peripheral resistance and greater blood volume place further strain on the heart and accelerates the process of damage to the myocardium. Vasoconstriction and fluid retention produce an increased hydrostatic pressure in the capillaries. This shifts the balance of forces in favour of interstitial fluid formation as the increased pressure forces additional fluid out of the blood, into the tissue. This results in edema (fluid build-up) in the tissues. In right-sided heart failure this commonly starts in the ankles where venous pressure is high due to the effects of gravity (although if the patient is bed-ridden, fluid accumulation may begin in the sacral region.) It may also occur in the abdominal cavity, where the fluid build-up is called ascites. In left-sided heart failure edema can occur in the lungs - this is called cardiogenic pulmonary edema. This reduces spare capacity for ventilation, causes stiffening of the lungs and reduces the efficiency of gas exchange by increasing the distance between the air and the blood. The consequences of this are dyspnea (shortness of breath), orthopnea and paroxysmal nocturnal dyspnea.
The symptoms of heart failure are largely determined by which side of the heart fails. The left side pumps blood into the systemic circulation, whilst the right side pumps blood into the pulmonary circulation. Whilst left-sided heart failure will reduce cardiac output to the systemic circulation, the initial symptoms often manifest due to effects on the pulmonary circulation. In systolic dysfunction, the ejection fraction is decreased, leaving an abnormally elevated volume of blood in the left ventricle. In diastolic dysfunction, end-diastolic ventricular pressure will be high. This increase in volume or pressure backs up to the left atrium and then to the pulmonary veins. Increased volume or pressure in the pulmonary veins impairs the normal drainage of the alveoli and favors the flow of fluid from the capillaries to the lung parenchyma, causing pulmonary edema. This impairs gas exchange. Thus, left-sided heart failure often presents with respiratory symptoms: shortness of breath, orthopnea and paroxysmal nocturnal dyspnea.
In severe cardiomyopathy, the effects of decreased cardiac output and poor perfusion become more apparent, and patients will manifest with cold and clammy extremities, cyanosis, claudication, generalized weakness, dizziness, and syncope.
The resultant hypoxia caused by pulmonary edema causes vasoconstriction in the pulmonary circulation, which results in pulmonary hypertension. Since the right ventricle generates far lower pressures than the left ventricle (approximately 20 mmHg versus around 120 mmHg, respectively, in the healthy individual) but nonetheless generates cardiac output exactly equal to the left ventricle, this means that a small increase in pulmonary vascular resistance causes a large increase in amount of work the right ventricle must perform. However, the main mechanism by which left-sided heart failure causes right-sided heart failure is actually not well understood. Some theories invoke mechanisms that are mediated by neurohormonal activation.[23] Mechanical effects may also contribute. As the left ventricle distends, the intraventricular septum bows into the right ventricle, decreasing the capacity of the right ventricle.
Systolic dysfunction
Heart failure caused by systolic dysfunction is more readily recognized. It can be simplistically described as failure of the pump function of the heart. It is characterized by a decreased ejection fraction (less than 45%). The strength of ventricular contraction is attenuated and inadequate for creating an adequate stroke volume, resulting in inadequate cardiac output. In general, this is caused by dysfunction or destruction of cardiac myocytes or their molecular components. In congenital diseases such as Duchenne muscular dystrophy, the molecular structure of individual myocytes is affected. Myocytes and their components can be damaged by inflammation (such as in myocarditis) or by infiltration (such as in amyloidosis). Toxins and pharmacological agents (such as ethanol, cocaine, and amphetamines) cause intracellular damage and oxidative stress. The most common mechanism of damage is ischemia causing infarction and scar formation. After myocardial infarction, dead myocytes are replaced by scar tissue, deleteriously affecting the function of the myocardium. On echocardiogram, this is manifest by abnormal or absent wall motion.
Because the ventricle is inadequately emptied, ventricular end-diastolic pressure and volumes increase. This is transmitted to the atrium. On the left side of the heart, the increased pressure is transmitted to the pulmonary vasculature, and the resultant hydrostatic pressure favors extravassation of fluid into the lung parenchyma, causing pulmonary edema. On the right side of the heart, the increased pressure is transmitted to the systemic venous circulation and systemic capillary beds, favoring extravassation of fluid into the tissues of target organs and extremities, resulting in dependent peripheral edema.
Diastolic dysfunction
Heart failure caused by diastolic dysfunction is generally described as the failure of the ventricle to adequately relax and typically denotes a stiffer ventricular wall. This causes inadequate filling of the ventricle, and therefore results in an inadequate stroke volume. The failure of ventricular relaxation also results in elevated end-diastolic pressures, and the end result is identical to the case of systolic dysfunction (pulmonary edema in left heart failure, peripheral edema in right heart failure.)
Diastolic dysfunction can be caused by processes similar to those that cause systolic dysfunction, particularly causes that affect cardiac remodeling.
Diastolic dysfunction may not manifest itself except in physiologic extremes if systolic function is preserved. The patient may be completely asymptomatic at rest. However, they are exquisitely sensitive to increases in heart rate, and sudden bouts of tachycardia (which can be caused simply by physiological responses to exertion, fever, or dehydration, or by pathological tachyarrhythmias such as atrial fibrillation with rapid ventricular response) may result in flash pulmonary edema. Adequate rate control (usually with a pharmacological agent that slows down AV conduction such as a calcium channel blocker or a beta-blocker) is therefore key to preventing decompensation.
Left ventricular diastolic function can be determined through echocardiography by measurement of various parameters such as the E/A ratio (early-to-atrial left ventricular filling ratio), the E (early left ventricular filling) deceleration time, and the isovolumic relaxation time.
Diagnosis
Acute pulmonary edema. Note enlarged heart size, apical vascular redistribution ( circle ), and small bilateral pleural effusions ( arrow ).
No system of diagnostic criteria has been agreed as the gold standard for heart failure. Commonly used systems are the "Framingham criteria"[24] (derived from the Framingham Heart Study), the "Boston criteria",[25] the "Duke criteria",[26] and (in the setting of acute myocardial infarction) the "Killip class".[27]
Imaging
Echocardiography is commonly used to support a clinical diagnosis of heart failure. This modality uses ultrasound to determine the stroke volume (SV, the amount of blood in the heart that exits the ventricles with each beat), the end-diastolic volume (EDV, the total amount of blood at the end of diastole), and the SV in proportion to the EDV, a value known as the ejection fraction (EF). In pediatrics, the shortening fraction is the preferred measure of systolic function. Normally, the EF should be between 50% and 70%; in systolic heart failure, it drops below 40%. Echocardiography can also identify valvular heart disease and assess the state of the pericardium (the connective tissue sac surrounding the heart). Echocardiography may also aid in deciding what treatments will help the patient, such as medication, insertion of an implantable cardioverter-defibrillator or cardiac resynchronization therapy. Echocardiography can also help determine if acute myocardial ischemia is the precipitating cause, and may manifest as regional wall motion abnormalities on echo.
Chest X-rays are frequently used to aid in the diagnosis of CHF. In the compensated patient, this may show cardiomegaly (visible enlargement of the heart), quantified as the cardiothoracic ratio (proportion of the heart size to the chest). In left ventricular failure, there may be evidence of vascular redistribution ("upper lobe blood diversion" or "cephalization"), Kerley lines, cuffing of the areas around the bronchi, and interstitial edema.
Electrophysiology
An electrocardiogram (ECG/EKG) may be used to identify arrhythmias, ischemic heart disease, right and left ventricular hypertrophy, and presence of conduction delay or abnormalities (e.g. left bundle branch block). Although these findings are not specific to the diagnosis of heart failure a normal ECG virtually excludes left ventricular systolic dysfunction.[28]
Blood tests
Blood tests routinely performed include electrolytes (sodium, potassium), measures of renal function, liver function tests, thyroid function tests, a complete blood count, and often C-reactive protein if infection is suspected. An elevated B-type natriuretic peptide (BNP) is a specific test indicative of heart failure. Additionally, BNP can be used to differentiate between causes of dyspnea due to heart failure from other causes of dyspnea. If myocardial infarction is suspected, various cardiac markers may be used.
According to a meta-analysis comparing BNP and N-terminal pro-BNP (NTproBNP) in the diagnosis of heart failure, BNP is a better indicator for heart failure and left ventricular systolic dysfunction. In groups of symptomatic patients, a diagnostic odds ratio of 27 for BNP compares with a sensitivity of 85% and specificity of 84% in detecting heart failure.[29]
Angiography
Heart failure may be the result of coronary artery disease, and its prognosis depends in part on the ability of the coronary arteries to supply blood to the myocardium (heart muscle). As a result, coronary catheterization may be used to identify possibilities for revascularisation through percutaneous coronary intervention or bypass surgery.
Monitoring
Various measures are often used to assess the progress of patients being treated for heart failure. These include fluid balance (calculation of fluid intake and excretion), monitoring body weight (which in the shorter term reflects fluid shifts).
Algorithms
There are various algorithms for the diagnosis of heart failure. For example, the algorithm used by the Framingham Heart Study adds together criteria mainly from physical examination. In contrast, the more extensive algorithm by the European Society of Cardiology (ESC) weights the difference between supporting and opposing parameters from the medical history, physical examination, further medical tests as well as response to therapy.
Framingham criteria
By the Framingham criteria, diagnosis of congestive heart failure (heart failure with impaired pumping capability)[6] requires the simultaneous presence of at least 2 of the following major criteria or 1 major criterion in conjunction with 2 of the following minor criteria:
Major criteria:[30]
- Cardiomegaly on chest radiography
- S3 gallop (a third heart sound)
- Acute pulmonary edema
- Paroxysmal nocturnal dyspnea
- Crackles on lung auscultation
- Central venous pressure of more than 16 cm H2O at the right atrium
- Jugular vein distension
- Positive abdominojugular test
- Weight loss of more than 4.5 kg in 5 days in response to treatment (sometimes classified as a minor criterium[31])
Minor criteria:[30]
- Tachycardia of more than 120 beats per minute
- Nocturnal cough
- Dyspnea on ordinary exertion
- Pleural effusion
- Decrease in vital capacity by one third from maximum recorded
- Hepatomegaly
- Bilateral ankle edema
Minor criteria are acceptable only if they can not be attributed to another medical condition such as pulmonary hypertension, chronic lung disease, cirrhosis, ascites, or the nephrotic syndrome.[30] The Framingham Heart Study criteria are 100% sensitive and 78% specific for identifying persons with definite congestive heart failure.[30]
ESC algorithm
The ESC algorithm weights the following parameters in establishing the diagnosis of heart failure:[32]
|
Influence
Parameter
|
Supports if present | Opposes if normal or absent |
|---|---|---|
| + - to some degree ++ - to intermediate degree |
||
| Compatible symptoms | ++ | ++ |
| Compatible signs | ++ | + |
| Cardiac dysfunction on echocardiography |
+++ | +++ |
| Response of symptoms or signs to therapy |
+++ | ++ |
| ECG | ||
| Normal | ++ | |
| Abnormal | ++ | + |
| Dysrhythmia | +++ | + |
| Laboratory | ||
| BNP > 400 pg/mL and/or NT-proBNP > 2000 pg/mL |
+++ | + |
| BNP < 100 pg/mL and NT-proBNP < 400 pg/mL |
+ | +++ |
| Hyponatraemia | + | + |
| Renal dysfunction | + | + |
| Mild elevations of troponin | + | + |
| Chest X-ray | ||
| Pulmonary congestion | +++ | + |
| Reduced exercise capacity | +++ | ++ |
| Abnormal pulmonary function tests | + | + |
| Abnormal haemodynamics at rest | +++ | ++ |
Management
Main article: Management of heart failure
Treatment focuses on improving the symptoms and preventing the progression of the disease. Reversible causes of the heart failure also need to be addressed: (e.g. infection, alcohol ingestion, anemia, thyrotoxicosis, arrhythmia, hypertension). Treatments include lifestyle and pharmacological modalities.
Acute decompensation
Main article: Acute decompensated heart failure
In acute decompensated heart failure (ADHF), the immediate goal is to re-establish adequate perfusion and oxygen delivery to end organs. This entails ensuring that airway, breathing, and circulation are adequate. Immediated treatments usually involve some combination of vasodilators such as nitroglycerin, diuretics such as furosemide, and possibly non invasive positive pressure ventilation (NIPPV).
Chronic management
The goal is to prevent the development of acute decompensated heart failure, to counteract the deleterious effects of cardiac remodeling, and to minimize the symptoms that the patient suffers. First-line therapy for all heart failure patients is angiotensin-converting enzyme (ACE) inhibition. ACE inhibitors (i.e., enalapril, captopril, lisinopril, ramipril) improve survival and quality of life in heart failure patients, and have been shown to reduce mortality in patients with left ventricular dysfunction in numerous randomized trials.[33][34] In addition to pharmacologic agents (oral loop diuretics, beta-blockers, ACE inhibitors or angiotensin receptor blockers, vasodilators, and in severe cardiomyopathy aldosterone receptor antagonists), behavioral modification should be pursued, specifically with regard to dietary guidelines regarding salt and fluid intake. Exercise should be encouraged as tolerated, as sufficient conditioning can significantly improve quality-of-life.
In patients with severe cardiomyopathy, implantation of an automatic implantable cardioverter defibrillator (AICD) should be considered. A select population will also probably benefit from ventricular resynchronization.
In select cases, cardiac transplantation can be considered. While this may resolve the problems associated with heart failure, the patient generally must remain on an immunosuppressive regimen to prevent rejection, which has its own significant downsides.
Home dobutamine and milrinone
These two medications are both inotropes with sympathomimetic effect. Both can be used in severe heart failure, generally in patients who require frequent exacerbations with hospitalization and/or refractory symptoms. While both medications have proven to improve symptoms, both also increase the risk of sudden cardiac death, and the research suggests an increased mortality rate for patients who are started on these medications. Extensive counseling about symptom management vs. risk of earlier death needs to be undertaken before starting the medication.[citation needed]
Palliative care
Patients with CHF often have significant symptoms, such as shortness of breath and chest pain. Both palliative care and cardiology are trying to get palliative care involved earlier in the course of patients with heart failure, and some would argue any patient with NYHA class III CHF should have a palliative care referral. Palliative care can not only provide symptom management, but also assist with advanced care planning, goals of care in the case of a significant decline, and making sure the patient has a medical power of attorney and discussed his or her wishes with this individual.
Hospice
Without transplantation, heart failure may not be reversible and cardiac function typically deteriorates with time. The growing number of patients with Stage IV heart failure (intractable symptoms of fatigue, shortness of breath or chest pain at rest despite optimal medical therapy) should be considered for palliative care or hospice, according to American College of Cardiology/American Heart Association guidelines.
Prognosis
Prognosis in heart failure can be assessed in multiple ways including clinical prediction rules and cardiopulmonary exercise testing. Clinical prediction rules use a composite of clinical factors such as lab tests and blood pressure to estimate prognosis. Among several clinical prediction rules for prognosing acute heart failure, the 'EFFECT rule' slightly outperformed other rules in stratifying patients and identifying those at low risk of death during hospitalization or within 30 days.[35] Easy methods for identifying low risk patients are:
- ADHERE Tree rule indicates that patients with blood urea nitrogen < 43 mg/dl and systolic blood pressure at least 115 mm Hg have less than 10% chance of inpatient death or complications.
- BWH rule indicates that patients with systolic blood pressure over 90 mm Hg, respiratory rate of 30 or less breaths per minute, serum sodium over 135 mmol/L, no new ST-T wave changes have less than 10% chance of inpatient death or complications.
A very important method for assessing prognosis in advanced heart failure patients is cardiopulmonary exercise testing (CPX testing). CPX testing is usually required prior to heart transplantation as an indicator of prognosis. Cardiopulmonary exercise testing involves measurement of exhaled oxygen and carbon dioxide during exercise. The peak oxygen consumption (VO2 max) is used as an indicator of prognosis. As a general rule, a VO2 max less than 12-14 cc/kg/min indicates a poor survival and suggests that the patient may be a candidate for a heart transplant. Patients with a VO2 max<10 cc/kg/min have clearly poorer prognosis. The most recent International Society for Heart and Lung Transplantation (ISHLT) guidelines[36] also suggest two other parameters that can be used for evaluation of prognosis in advanced heart failure, the heart failure survival score and the use of a criterion of VE/VCO2 slope > 35 from the CPX test. The heart failure survival score is a score calculated using a combination of clinical predictors and the VO2 max from the cardiopulmonary exercise test.
Epidemiology
Mostly as a result of the costs of hospitalization, it is associated with a high health expenditure; costs have been estimated to amount to 2% of the total budget of the National Health Service in the United Kingdom, and more than $35 billion in the United States.[37][38] Heart failure is associated with significantly reduced physical and mental health, resulting in a markedly decreased quality of life.[39][40] With the exception of heart failure caused by reversible conditions, the condition usually worsens with time. Although some people survive many years, progressive disease is associated with an overall annual mortality rate of 10%.[41]
Heart failure is the leading cause of hospitalization in people older than 65.[42] In developed countries, the mean age of patients with heart failure is 75 years old. In developing countries, two to three percent of the population suffers from heart failure, but in those 70 to 80 years old, it occurs in 20—30 percent.
Heart failure affects close to 5 million people in the USA and each year close to 500,000 new cases are diagnosed. What is of more concern is that more than 50% of patients seek re-admission within 6 months after treatment and the average duration of hospital stay is 6 days.
In tropical countries, the most common cause of HF is valvular heart disease or some type of cardiomyopathy. Moreover as underdeveloped countries become more affluent, there has also been an increase in diabetes, hypertension and obesity which has resulted in heart failure.
In USA, HF is much higher in African Americans, Hispanics, Native Americans and recent immigrants from the eastern bloc countries like Russia. This high prevalence in these ethnic populations has been linked to high incidence of diabetes and hypertension. In many new immigrants to the USA the high prevalence of heart failure has largely been attributed to lack of preventive health care or substandard treatment.[43]
Sex
Men have a higher incidence of heart failure, but the overall prevalence rate is similar in both sexes, since women survive longer after the onset of heart failure.[44] Women tend to be older when diagnosed with heart failure (after menopause), they are more likely than men to have diastolic dysfunction, and seem to experience a lower overall quality of life than men after diagnosis.[44]
Race
New information suggests that elements of heart failure in African Americans and Caucasians may be different[45] and therapy for heart failure has different efficacies depending on racial, ethnic, and genetic backgrounds.
References
- ^ "heart failure" at Dorland's Medical Dictionary
- ^ mayoclinic.com > Heart failure Dec. 23, 2009
- ^ medterms.com > Definition of Heart failure Last Editorial Review: 6/18/2002
- ^ a b c McMurray JJ, Pfeffer MA (2005). "Heart failure". Lancet 365 (9474): 1877–89. DOI:10.1016/S0140-6736(05)66621-4. PMID 15924986.
- ^ Dickstein K, Cohen-Solal A, Filippatos G, et al. (October 2008). "ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)". Eur. Heart J. 29 (19): 2388–442. DOI:10.1093/eurheartj/ehn309. PMID 18799522. http://eurheartj.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=18799522.
- ^ a b "congestive heart failure" at Dorland's Medical Dictionary
- ^ "high-output heart failure" at Dorland's Medical Dictionary
- ^ Jessup. M, et al. 2009 Focused Update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults. Circulation. 2009 Apr 14;119(14):1977-2016. PMID 19324967
- ^ Criteria Committee, New York Heart Association. Diseases of the heart and blood vessels. Nomenclature and criteria for diagnosis, 6th ed. Boston: Little, Brown and Co., 1964;114.
- ^ Raphael C, Briscoe C, Davies J, et al. (2007). "Limitations of the New York Heart Association functional classification system and self‐reported walking distances in chronic heart failure". Heart 93 (4): 476–82. DOI:10.1136/hrt.2006.089656. PMC 1861501. PMID 17005715. //www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1861501.
- ^ Hunt SA, Abraham WT, Chin MH, et al. (2005). "ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult" (PDF). Circulation 112 (12): e154–235. DOI:10.1161/CIRCULATIONAHA.105.167586. PMID 16160202. http://circ.ahajournals.org/cgi/reprint/112/12/e154.pdf.
- ^ He J; Ogden LG; Bazzano LA; Vupputuri S, et al. (2001). "Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study". Arch. Intern. Med. 161 (7): 996–1002. DOI:10.1001/archinte.161.7.996. PMID 11295963.
- ^ Baldasseroni S; Opasich C; Gorini M; Lucci D, et al. (2002). "Left bundle-branch block is associated with increased 1-year sudden and total mortality rate in 5517 outpatients with congestive heart failure: a report from the Italian network on congestive heart failure". American Heart Journal 143 (3): 398–405. DOI:10.1067/mhj.2002.121264. PMID 11868043.
- ^ Fonarow GC, Abraham WT, Albert NM, et al. (April 2008). "Factors Identified as Precipitating Hospital Admissions for Heart Failure and Clinical Outcomes: Findings From OPTIMIZE-HF". Arch. Intern. Med. 168 (8): 847–854. DOI:10.1001/archinte.168.8.847. PMID 18443260.
- ^ Nieminen MS, Böhm M, Cowie MR, et al. (February 2005). "Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology". Eur. Heart J. 26 (4): 384–416. DOI:10.1093/eurheartj/ehi044. PMID 15681577. http://eurheartj.oxfordjournals.org/cgi/content/full/26/4/384.
- ^ Boron and Boulpaep 2005 Medical Physiology Updated Edition p533 ISBN 0-7216-3256-4
- ^ Rang HP (2003). Pharmacology. Edinburgh: Churchill Livingstone. pp. 127. ISBN 0-443-07145-4.
- ^ cardiac pathophysiology in heart failure at GPnotebook
- ^ Shigeyama J, Yasumura Y, Sakamoto A, et al. (December 2005). "Increased gene expression of collagen Types I and III is inhibited by beta-receptor blockade in patients with dilated cardiomyopathy". Eur. Heart J. 26 (24): 2698–705. DOI:10.1093/eurheartj/ehi492. PMID 16204268.
- ^ Tsutsui H, Matsushima S, Kinugawa S, et al. (May 2007). "Angiotensin II type 1 receptor blocker attenuates myocardial remodeling and preserves diastolic function in diabetic heart" (– Scholar search). Hypertens. Res. 30 (5): 439–49. DOI:10.1291/hypres.30.439. PMID 17587756. http://joi.jlc.jst.go.jp/JST.JSTAGE/hypres/30.439?from=PubMed. [dead link]
- ^ Krug AW, Grossmann C, Schuster C, et al. (October 2003). "Aldosterone stimulates epidermal growth factor receptor expression". J. Biol. Chem. 278 (44): 43060–6. DOI:10.1074/jbc.M308134200. PMID 12939263.
- ^ systemic pathophysiology in heart failure at GPnotebook
- ^ Hunter JG, Boon NA, Davidson S, Colledge NR, Walker B (2006). Davidson's principles & practice of medicine. Elsevier/Churchill Livingstone. pp. 544. ISBN 0-443-10057-8.
- ^ McKee PA, Castelli WP, McNamara PM, Kannel WB (1971). "The natural history of congestive heart failure: the Framingham study". N. Engl. J. Med. 285 (26): 1441–6. DOI:10.1056/NEJM197112232852601. PMID 5122894.
- ^ Carlson KJ, Lee DC, Goroll AH, Leahy M, Johnson RA (1985). "An analysis of physicians' reasons for prescribing long-term digitalis therapy in outpatients". Journal of chronic diseases 38 (9): 733–9. DOI:10.1016/0021-9681(85)90115-8. PMID 4030999.
- ^ Harlan WR, oberman A, Grimm R, Rosati RA (1977). "Chronic congestive heart failure in coronary artery disease: clinical criteria". Ann. Intern. Med. 86 (2): 133–8. PMID 835934.
- ^ Killip T, Kimball JT (1967). "Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients". Am. J. Cardiol. 20 (4): 457–64. DOI:10.1016/0002-9149(67)90023-9. PMID 6059183.
- ^ Loscalzo, Joseph; Fauci, Anthony S.; Braunwald, Eugene; Dennis L. Kasper; Hauser, Stephen L; Longo, Dan L. (2008). Harrison's Principles of Internal Medicine (17 ed.). McGraw-Hill Medical. pp. 1447. ISBN 978-0-07-147693-5.
- ^ Ewald B, Ewald D, Thakkinstian A, Attia J (2008). "Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction". Intern Med J 38 (2): 101–13. DOI:10.1111/j.1445-5994.2007.01454.x. PMID 18290826. http://www.blackwell-synergy.com/doi/abs/10.1111/j.1445-5994.2007.01454.x.
- ^ a b c d medicalcriteria.com > Framingham Criteria for Congestive Heart Failure In turn citing: McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Engl J Med. 1971 Dec 23;285(26):1441-6.
- ^ Topic Review - Heart Failure By Osama Gusbi, MD. Albany Medical Review - January 2002
- ^ [ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/guidelines-HF-FT.pdf] European Heart Journal (2008) 29, 2388–2442, doi:10.1016/j.ejheart.2008.08.005
- ^ The CONSENSUS Trial Study Group. (1987). "Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)". N Engl J Med. 316 (23): 1429–35. DOI:10.1056/NEJM198706043162301. PMID 2883575.
- ^ The SOLVD Investigators. (1991). "Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure". N Engl J Med 325 (5): 293–302. DOI:10.1056/NEJM199108013250501. PMID 2057034.
- ^ Auble TE, Hsieh M, McCausland JB, Yealy DM (2007). "Comparison of four clinical prediction rules for estimating risk in heart failure". Annals of Emergency Medicine 50 (2): 127–35, 135.e1–2. DOI:10.1016/j.annemergmed.2007.02.017. PMID 17449141.
- ^ Mandeep R. Mehra et al. "Evaluation of listing criteria for cardiac transplantation". Journal of Heart and Lung Transplantation. http://www.jhltonline.org/article/PIIS1053249806004608/fulltext#sec1. Retrieved 8 April 2010.
- ^ Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ (June 2002). "The current cost of heart failure to the National Health Service in the UK". Eur. J. Heart Fail. 4 (3): 361–71. DOI:10.1016/S1388-9842(01)00198-2. PMID 12034163. http://linkinghub.elsevier.com/retrieve/pii/S1388984201001982.
- ^ Rosamond W, Flegal K, Furie K, et al. (January 2008). "Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee". Circulation 117 (4): e25–146. DOI:10.1161/CIRCULATIONAHA.107.187998. PMID 18086926. http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=18086926.
- ^ Juenger J, Schellberg D, Kraemer S, et al. (March 2002). "Health related quality of life in patients with congestive heart failure: comparison with other chronic diseases and relation to functional variables". Heart 87 (3): 235–41. DOI:10.1136/heart.87.3.235. PMC 1767036. PMID 11847161. http://heart.bmj.com/cgi/pmidlookup?view=long&pmid=11847161.
- ^ Hobbs FD, Kenkre JE, Roalfe AK, Davis RC, Hare R, Davies MK (December 2002). "Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population". Eur. Heart J. 23 (23): 1867–76. DOI:10.1053/euhj.2002.3255. PMID 12445536. http://eurheartj.oxfordjournals.org/cgi/pmidlookup?view=long&pmid=12445536.
- ^ Neubauer S (2007). "The failing heart — an engine out of fuel". N Engl J Med 356 (11): 1140–51. DOI:10.1056/NEJMra063052. PMID 17360992.
- ^ Krumholz HM, Chen YT, Wang Y, Vaccarino V, Radford MJ, Horwitz RI (2000). "Predictors of readmission among elderly survivors of admission with heart failure". Am. Heart J. 139 (1 Pt 1): 72–7. DOI:10.1016/S0002-8703(00)90311-9. PMID 10618565.
- ^ Heart Failure Information, Retrieved on 2010-01-21.
- ^ a b Strömberg A, Mårtensson J. (Apr 2003). "Gender differences in patients with heart failure". Eur. J. Cardiovasc. Nurs. 2 (1): 7–18. DOI:10.1016/S1474-5151(03)00002-1. PMID 14622644.
- ^ Aronow, WS; Ahn C, Kronzon, I (1999). "Comparison of incidence of congestive heart failure in older African-Americans, Hispanics, and Caucasians". Am J of Cardiol 84 (5): 611–2. DOI:10.1016/S0002-9149(99)00392-6. PMID 10482169.
External links
| Wikimedia Commons has media related to: Heart failure |
- American Heart Association's Heart Failure web site - information and resources for treating and living with heart failure.
- Heart Failure Matters – patient information website of the Heart Failure Association of the European Society of Cardiology
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 無症候性左室収縮不全の臨床症状と診断 clinical manifestations and diagnosis of asymptomatic left ventricular systolic dysfunction
- 2. 無症候性左室収縮不全のマネージメントと予後 management and prognosis of asymptomatic left ventricular systolic dysfunction
- 3. 駆出率低下を伴う心不全の治療の概要 overview of the therapy of heart failure with reduced ejection fraction
- 4. Use of angiotensin receptor-neprilysin inhibitor in heart failure with reduced ejection fraction
- 5. 心不全または心筋症患者の病因及び重症度の決定 determining the etiology and severity of heart failure or cardiomyopathy
English Journal
- EGLN1 variants influence expression and SaO2 levels to associate with high-altitude pulmonary oedema and adaptation.
- Mishra A, Mohammad G, Thinlas T, Pasha MA.SourceDepartment of Medicine, Sonam Norboo Memorial Hospital, Leh, Ladakh, Jammu & Kashmir, India.
- Clinical science (London, England : 1979).Clin Sci (Lond).2013 Apr;124(7):479-89. doi: 10.1042/CS20120371.
- EGLN1 [encoding HIF (hypoxia-inducible factor)-prolyl hydroxylase 2] plays a pivotal role in the HIF pathway and has emerged as one of the most intriguing genes with respect to physiology at HA (high altitude). EGLN1, being an actual oxygen sensor, appears to have a potential role in the functional
- PMID 23130672
- Direct renin inhibition prevents cardiac dysfunction in a diabetic mouse model: comparison with an angiotensin receptor antagonist and angiotensin-converting enzyme inhibitor.
- Thomas CM, Yong QC, Seqqat R, Chandel N, Feldman DL, Baker KM, Kumar R.SourceDivision of Molecular Cardiology, Department of Medicine, Texas A&M Health Science Center, College of Medicine; Scott and White; Central Texas Veterans Health Care System, Temple, TX 76504, USA.
- Clinical science (London, England : 1979).Clin Sci (Lond).2013 Apr;124(8):529-41. doi: 10.1042/CS20120448.
- Hyperglycaemia up-regulates intracellular AngII (angiotensin II) production in cardiac myocytes, effects of which are blocked more effectively by renin inhibition than ARBs (angiotensin receptor blockers) or ACEis (angiotensin-converting enzyme inhibitors). In the present study, we determined whethe
- PMID 23116220
- MCARD-Mediated Gene Transfer of GRK2 Inhibitor in Ovine Model of Acute Myocardial Infarction.
- Swain JD, Fargnoli AS, Katz MG, Tomasulo CE, Sumaroka M, Richardville KC, Koch WJ, Rabinowitz JE, Bridges CR.SourceDepartment of Surgery, Division of Cardiovascular Surgery, University of Pennsylvania Medical Center, Philadelphia, PA, USA.
- Journal of cardiovascular translational research.J Cardiovasc Transl Res.2013 Apr;6(2):253-62. doi: 10.1007/s12265-012-9418-z. Epub 2012 Dec 1.
- β-Adrenergic receptor (βAR) dysfunction in acute myocardial infarction (MI) is associated with elevated levels of the G-protein-coupled receptor kinase-2 (GRK2), which plays a key role in heart failure progression. Inhibition of GRK2 via expression of a peptide βARKct transferred by molecular car
- PMID 23208013
Japanese Journal
- An EP4 Receptor Agonist Inhibits Cardiac Fibrosis Through Activation of PKA Signaling in Hypertrophied Heart
- International Heart Journal 58(1), 107-114, 2017
- NAID 130005330538
- Congenitally Corrected Transposition of the Great Arteries and Situs Inversus in an Octogenarian With Systemic Right Ventricular Failure
- International Heart Journal 58(1), 151-154, 2017
- NAID 130005330356
- Prognostic Significance of Non-Dilated Left Ventricular Size and Mitral Regurgitation in Patients With Dilated Phase of Hypertrophic Cardiomyopathy
- International Heart Journal 58(1), 63-68, 2017
- NAID 130005330354
Related Links
- Systolic dysfunction refers to impaired ventricular contraction. In chronic heart failure, this is most likely due to changes in the signal transduction mechanisms regulating cardiac excitation-contraction coupling. The loss of cardiac inotropy ( i.e., ...
Related Pictures
★リンクテーブル★
| リンク元 | 「収縮不全」「systolic heart failure」 |
| 関連記事 | 「dysfunction」「systolic」 |
「収縮不全」
「systolic heart failure」
「dysfunction」
- n.
- vi
- 機能不全に陥る
- 関
- barrier、damage、difficulty、disorder、disturbance、foe、functional disorder、functional impairment、hindrance、hypofunction、impair、impairment、impediment、incompetence、insufficiency、lesion、malfunction、obstacle、stun
「systolic」
- adj.
- 収縮期の、収縮期性の
- 関
- systole